Pharmaceutical

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

Vancouver, Canada, June 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

1 month ago

Vanqua Bio to Present at Inaugural GBA1 2024 Meeting

CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for…

1 month ago

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members…

1 month ago

Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG…

1 month ago

Sensitech to Strengthen Life Sciences Cold Chain Solutions with Acquisition of Berlinger & Co. Monitoring Solutions

BEVERLY, Mass., June 19, 2024  /PRNewswire/ -- Carrier Global Corporation, on behalf of its Sensitech business, a world leader in…

1 month ago

Prime/MRx’s new Pharmacy Match technology-driven solution expands specialty pharmacy access and choice

Using real-time pricing, Pharmacy Match drives affordability for plan sponsors while offering access to the most competitive pharmacy for each…

1 month ago

Vita Global Sciences Partners with Veeva to Streamline Clinical Data Management

CRO will use Veeva Vault EDC to deliver a better experience to patients, research sites, and sponsors PLEASANTON, Calif., June…

1 month ago

Gilead and Kite Pharma Celebrates Pride Month

NORTHAMPTON, MA / ACCESSWIRE / June 19, 2024 / Gilead SciencesGilead and Kite Pharma teams raised Pride Month flags at…

1 month ago

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

1 month ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain…

1 month ago